0000000000279996

AUTHOR

Hazel Lote

showing 3 related works from this author

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer

2018

There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 cases ctDNA…

neoplasmsdigestive system diseases
researchProduct

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients

2016

Summary Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab.

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPathologyGenotypeColorectal cancermedicine.medical_treatmentOriginal ManuscriptSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmicroRNAmedicineHumansOncology & CarcinogenesisProgression-free survivalNeoadjuvant therapyAgedRetrospective StudiesCetuximabRectal Neoplasmsbusiness.industryChemoradiotherapyGeneral MedicineMiddle Agedmedicine.diseaseChemotherapy regimenNeoadjuvant Therapy3. Good healthRadiation therapyMicroRNAs030104 developmental biology030220 oncology & carcinogenesisFemalebusiness1112 Oncology And Carcinogenesismedicine.drug
researchProduct

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

2018

Abstract There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 ca…

MaleProto-Oncogene Proteins B-rafOrganoplatinum CompoundsScienceCetuximabArticleCirculating Tumor DNAProto-Oncogene Proteins p21(ras)SDG 3 - Good Health and Well-beingAntineoplastic Combined Chemotherapy ProtocolsJournal ArticleHumansneoplasmsCapecitabineDigestive System Surgical ProceduresAgedRectal NeoplasmsQRChemoradiotherapy AdjuvantMiddle AgedPrognosisdigestive system diseasesOxaliplatinTreatment OutcomeMutation/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingMedicineFemaleScientific reports
researchProduct